Spots Global Cancer Trial Database for EO4010 in Previously Treated Metastatic Colorectal Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: EO4010 in Previously Treated Metastatic Colorectal Carcinoma
Official Title: A Global Multicenter Phase 1/2 Trial of EO4010, a Novel Microbial Derived Peptide Therapeutic Vaccine, in Combination With Nivolumab, for Treatment of Patients With Previously Treated Metastatic Colorectal Carcinoma
Study ID: NCT05589597
Conditions
Interventions
Study Description
Brief Summary: Open-label multicenter study
Detailed Description: This is an open-label, multicenter, FIH, phase 1/2 trial to assess safety, tolerability, immunogenicity, and preliminary efficacy of the microbial-derived therapeutic vaccine EO4010 in combination with nivolumab for treatment of patients with unresectable, previously treated, metastatic colorectal cancer
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
MD Anderson, Houston, Texas, United States
Hôpital Jean Minjoz, Besançon, , France
ICM Val d'Aurelle, Montpellier, , France
Saint Antoine hospital, Paris, , France
Hospital Universitari Vall d'Hebron, Barcelona, , Spain
Contact Details
Name: Jan Fagerberg
Affiliation: Enterome
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
